In Coding
Oct 31st, 2019
Recently established coverage of the revolutionary cancer therapy Chimeric Antigen Receptor T-cell (CAR T-cell) provides Medicare patients with access to this cutting-edge treatment. The article Innovative CAR T-Cell Cancer Therapy Now Available to Medicare Beneficiaries breaks down Gilead Sciences’ Yescarta (axicabtagene ciloleucel) for acute lymphoblastic leukemia and Novartis’ Kymriah (tisagen...
In CMS
Aug 27th, 2019
Now that revolutionary cancer therapy, Chimeric Antigen Receptor T-cell (CAR T-cell), is covered, let’s take a look at coding CAR-T. Last month the Centers for Medicare & Medicaid Services (CMS) finalized the long-sought rules for coverage of CAR-T, novel cutting-edge, often curative treatments that utilize the patients’ own genetically modified immune cells to fight cancer. The ...